

Miklos Rohla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6686395/publications.pdf>

Version: 2024-02-01

15
papers

266
citations

1040056

9
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

558
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	2.0	4
2	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006852.	2.2	11
3	Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. <i>American Heart Journal</i> , 2020, 228, 98-108.	2.7	11
4	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020, 318, 67-73.	1.7	11
5	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019, 132, 749-757.e5.	1.5	48
6	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019, 9, e022478.	1.9	50
7	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	1.7	38
8	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. <i>International Journal of Cardiology</i> , 2018, 270, 160-166.	1.7	24
9	Lowering blood pressure in primary care in Vienna (LOW-BP-VIENNA). <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 698-706.	1.9	2
10	Awareness, treatment, and control of hypertension in Austria. <i>Journal of Hypertension</i> , 2016, 34, 1432-1440.	0.5	13
11	Impact of bivalirudin on mortality and bleeding complications in acute coronary syndrome patients undergoing invasive revascularization. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 906-915.	1.9	1
12	Long-term mortality of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation for acute and stable coronary artery disease. <i>International Journal of Cardiology</i> , 2015, 184, 108-114.	1.7	24
13	Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 191-197.	3.0	15
14	Stroke and recurrent left atrial appendage thrombus in a patient with atrial fibrillation under old and new oral anticoagulants: A case report. <i>Thrombosis and Haemostasis</i> , 2014, 111, 375-378.	3.4	0
15	Metabolic syndrome, inflammation and atherothrombosis. <i>Hamostaseologie</i> , 2013, 33, 283-294.	1.9	13